Dr. Doreen Ezeife, MD, FRCPC, Staff Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta discusses new data presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) that highlighted the value of using the Guardant360 ® Liquid Biopsy Blood Test to evaluate a patient’s advanced non-small cell lung cancer (NSCLC) to help guide treatment decisions and reduce cost compared to tissue biopsy alone. The majority of the savings are derived from a patient receiving a targeted therapy that is designed to address their particular cancer rather than undergoing costly chemotherapy and immunotherapies that might not help them.
Dr. Doreen Ezeife is a Staff Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. She completed her medical degree at the University of Toronto. She did her Internal Medicine and Medical Oncology residency training in Calgary followed by a Thoracic Oncology fellowship at Princess Margaret Cancer Centre and a Master of Science in Health Technology Assessment and Health Services Research at the University of Toronto. She is a Fellow of the Royal College of Physicians of Canada in Internal Medicine (2014) and Medical Oncology (2017).Doreen’s research focuses on cancer drug access, drug funding and assessing the value of new cancer treatments. Doreen is the recipient of some prestigious awards for her important research including the Novartis Oncology Young Canadian Investigator Award, Canadian Association of Medical Oncologists’ Fellowship Award, and she has received peer-reviewed grant funding from CIHR, the Alberta Cancer Foundation and Cancer Care Ontario.